Savara to Present at H.C. Wainwright BioConnect Investor Conference

Event summary

  • Savara Inc. will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19, 2026.
  • The event will be held at the NASDAQ headquarters in New York, NY, at 10:00 AM ET.
  • The live webcast and replay will be available on Savara’s corporate website for 90 days.
  • Savara’s lead program, MOLBREEVI, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

The big picture

Savara’s participation in the H.C. Wainwright BioConnect Investor Conference underscores its focus on engaging with investors as it advances its lead candidate, MOLBREEVI, through critical Phase 3 trials. The event provides a platform for the company to highlight its expertise in rare respiratory diseases and its proprietary delivery system, potentially influencing market perception ahead of key regulatory milestones.

What we're watching

Clinical Progress
The pace at which MOLBREEVI advances through Phase 3 trials will determine Savara’s near-term valuation.
Investor Sentiment
How the fireside chat impacts investor confidence in Savara’s pipeline and execution capabilities.
Regulatory Pathway
Whether Savara can secure FDA and EMA approval for MOLBREEVI, given its conditional trade name status.